Scrutinizing anticompetitive behavior in the health care sector that limits choice of and access to quality care is at the top of the agenda for the Federal Trade Commission (FTC), especially cracking down on common business practices used by pharmacy benefit managers that impact the affordability of prescription drugs and threaten the operations of other drug industry stakeholders like pharmacies, FTC Chair Lina Khan said during an interview with MedPage Today Friday (May 10). Khan’s remarks, however, come as...